CLINICAL PHARMACOLOGY & EARLY HUMAN STUDIES - 2017/8

Module code: PHMM037

Module provider

School of Biosciences and Medicine

Module Leader

TRINDER S Dr (Biosc & Med)

Number of Credits

15

ECT Credits

7.5

Framework

FHEQ Level 7

JACs code

B190

Module cap (Maximum number of students)

N/A

Module Availability

Semester 2

Overall student workload

Workshop Hours: 6

Independent Study Hours: 120

Lecture Hours: 26

Tutorial Hours: 8

Assessment pattern

Assessment type Unit of assessment Weighting
Coursework Home Assignment - Question 1 50%
Coursework Home Assignment - Question 2 50%

Alternative Assessment

N/A

Prerequisites / Co-requisites

Learning outcomes

Attributes Developed
A systematic understanding of knowledge and a critical awareness of clinical pharmacology and how they are applied in developing a new medicine with regard to current problems and new insights. KCT
A comprehensive understanding of the techniques of simple non-compartmental pharmacokinetic analysis of blood/plasma/serum concentration data (to construct a blood/plasma/serum concentration versus time curve and derive/interpret the key parameters AUC, t1/2, Tmax, Cmax and VD).( C, K, T) KCT
Thorough interpretation of concentration-effect relationships. KCT
Critical evaluation of the sources of PK and PD variability and the methods of assessing these. KT
Critical evaluation and development of a drug development plan and design key clinical pharmacology studies based on the target profile, preclinical investigations and other data. CPT
Systematic understanding of the key ethical and quality issues in doing early human studies. KT

Attributes Developed

C - Cognitive/analytical

K - Subject knowledge

T - Transferable skills

P - Professional/Practical skills

Module content

Methods of Teaching / Learning

Assessment Strategy


The assessment strategy is designed to provide students with the opportunity to demonstrate

•     A systematic understanding of knowledge and a critical awareness of clinical pharmacology and how they are applied in developing a new medicine with regard to current problems and new insights.

•     A comprehensive understanding of the techniques of simple non-compartmental pharmacokinetic analysis of blood/plasma/serum concentration data (to construct a blood/plasma/serum concentration versus time curve and derive/interpret the key parameters AUC, t1/2, Tmax, Cmax and VD).

•     Interpretation of concentration-effect relationships.

•     Critically evaluation of the sources of PK and PD variability and the methods

•     Evaluation and development of a drug development plan and design key clinical pharmacology studies based on the target profile, preclinical investigations and other data.

•     Systematic understanding of the key ethical and quality issues in doing early human studies

 

Thus, the summative assessment for this module consists of:


Two post module assignments which are two units of assessment. Each unit is weighted at 50% of the total module mark and the pass mark is 50% overall.


 

Formative assessment and feedback

 

Students are given formative feedback each morning of day 2, 3, 4 and 5 of the module when they give their syndicate presentations from the previous evenings syndicate work. In addition on day 5 the syndicate presentations are to the module teaching team in the form of a clinical development plan for the drug(s) studied.

Reading list

Reading list for CLINICAL PHARMACOLOGY & EARLY HUMAN STUDIES : http://aspire.surrey.ac.uk/modules/phmm037

Please note that the information detailed within this record is accurate at the time of publishing and may be subject to change. This record contains information for the most up to date version of the programme / module for the 2017/8 academic year.